A Relative Bioavailability Study of Moexipril HCl 15 mg Tablets Under Fasting Conditions

A Relative Bioavailability Study of Moexipril HCl 15mg Tablets Under Fasting Conditions

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00992862

Enrollment

Registered

2009-10-09

Start date

Unknown

Completion date

Unknown

Last updated

2013-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

The purpose of this study is to compare the relative bioavailability of Moexipril HCl 15mg tablets (by Paddock Laboratories, Inc.) with that of Univasc® 15mg tablets (by Schwarz Pharma) following a single oral dose (1 x 15mg tablet) in healthy, adult subjects under fasting conditions.

Interventions

DRUGMoexipril HCl 15mg Tablets, Paddock Laboratories, Inc.

DRUGUnivasc® 15mg Tablets

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Good health as determined by lack of clinically significant abnormalities in health assessment performed at screening

Exclusion criteria

* Positive test results for HIV or Hepatitis B or C * History of allergy or sensitivity to Moexipril HCl or related drugs

Design outcomes

Primary

Measure	Time frame
Bioequivalence according to US FDA guidelines	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026